Aurelia Lamanuzzi
Overview
Explore the profile of Aurelia Lamanuzzi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
413
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saltarella I, Link A, Lamanuzzi A, Reichen C, Robinson J, Altamura C, et al.
Biomed Pharmacother
. 2024 Jun;
176:116877.
PMID: 38850654
Multiple myeloma (MM) progression is closely dependent on cells in the bone marrow (BM) microenvironment, including fibroblasts (FBs) and immune cells. In their BM niche, MM cells adhere to FBs...
2.
Lamanuzzi A, Saltarella I, Reale A, Melaccio A, Solimando A, Altamura C, et al.
Biomedicines
. 2023 May;
11(5).
PMID: 37239071
Extracellular vesicles (EVs) have emerged as important players in cell-to-cell communication within the bone marrow (BM) of multiple myeloma (MM) patients, where they mediate several tumor-associated processes. Here, we investigate...
3.
Tolomeo D, Traversa D, Venuto S, Ebbesen K, Garcia Rodriguez J, Tamma G, et al.
Genes Chromosomes Cancer
. 2022 Dec;
62(7):377-391.
PMID: 36562080
Small cell lung cancer (SCLC) is treated as a homogeneous disease, although the expression of NEUROD1, ASCL1, POU2F3, and YAP1 identifies distinct molecular subtypes. The MYC oncogene, amplified in SCLC,...
4.
Melaccio A, Reale A, Saltarella I, Desantis V, Lamanuzzi A, Cicco S, et al.
J Clin Med
. 2022 Nov;
11(21).
PMID: 36362718
Multiple myeloma (MM) is the second most common hematological malignancy, and despite the introduction of innovative therapies, remains an incurable disease. Identifying early and minimally or non-invasive biomarkers for predicting...
5.
Saltarella I, Altamura C, Lamanuzzi A, Apollonio B, Vacca A, Frassanito M, et al.
Int J Mol Sci
. 2022 Jul;
23(13).
PMID: 35806308
Ion channels are pore-forming proteins that allow ions to flow across plasma membranes and intracellular organelles in both excitable and non-excitable cells. They are involved in the regulation of several...
6.
Cicco S, Desantis V, Vacca A, Cazzato G, Solimando A, Cirulli A, et al.
Front Med (Lausanne)
. 2022 Jun;
9:863150.
PMID: 35652080
Background: Takayasu Arteritis (TAK) increases vascular stiffness and arterial resistance. Atherosclerosis leads to similar changes. We investigated possible differences in cardiovascular remodeling between these diseases and whether the differences are...
7.
Saltarella I, Apollonio B, Lamanuzzi A, Desantis V, Mariggio M, Desaphy J, et al.
Cancers (Basel)
. 2022 Apr;
14(8).
PMID: 35454868
Long non-coding RNAs (lncRNAs) are transcripts longer than 200 nucleotides that are not translated into proteins. Nowadays, lncRNAs are gaining importance as key regulators of gene expression and, consequently, of...
8.
Saltarella I, Lamanuzzi A, Desantis V, Di Marzo L, Melaccio A, Curci P, et al.
J Pathol
. 2021 Dec;
256(4):402-413.
PMID: 34919276
Multiple myeloma (MM) progression and drug resistance depend on the crosstalk between MM cells and bone marrow (BM) fibroblasts (FBs). During monoclonal gammopathy of undetermined significance (MGUS) to MM transition,...
9.
Saltarella I, Lamanuzzi A, Apollonio B, Desantis V, Bartoli G, Vacca A, et al.
Cells
. 2021 Nov;
10(11).
PMID: 34831408
Multiple myeloma (MM) progression closely depends on the bidirectional crosstalk between tumor cells and the surrounding microenvironment, which leads to the creation of a tumor supportive niche. Extracellular vesicles (EVs)...
10.
Desantis V, Solimando A, Saltarella I, Sacco A, Giustini V, Bento M, et al.
Cancers (Basel)
. 2021 Aug;
13(15).
PMID: 34359551
Multiple myeloma (MM) is a hematological malignancy characterised by proliferation of clonal plasma cells (PCs) within the bone marrow (BM). Myelomagenesis is a multi-step process which goes from an asymptomatic...